BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€294.00RxjfjcTlslmklk

Narrow-Moat BioMerieux on Track for Record Year; BioFire Propelling Strength Through Pandemic

Narrow-moat BioMerieux reported strong third-quarter results, with reported growth of 21% (26.5% at constant currency) driven by 120% product line growth of BioFire respiratory panel 2.1, a syndromic approach to COVID-19 detection. We may tweak our model to account for the firm’s outperformance, but we do not anticipate a material change to our EUR 65 fair value estimate.

Sponsor Center